Physical state of drugs precipitated in confined spaces

In this project Disruptive Pharma, a pioneering pharmaceutical company, partners with RISE to study the physical state of APIs precipitated within the pores of MMC using nano-focused X-ray beams. Synchrotron facilities such as MAX IV (Sweden), ESRF (France) or DLS (UK) offer unique capabilities to explore the structural characteristics of these confined systems. 

By examining mechanisms that drive drug precipitation one can unravel critical insights into drug stability, solubility, and release behaviour which can open a wide range of opportunities for pharmaceutical research and development. 

It is expected that the results of these experiments will increase the potential to refine drug delivery systems, enhance bioavailability, and adjust therapeutic efficacy. The interplay between the synchrotron technology and pharmaceutical science creates opportunities for innovative formulations, ensuring that specific interactions between API and porous matrices are deciphered.